Table 3.

Multivariable models of RCB 0/I and pCR

A. PrECOG 0105 Cohort (N = 70)
RCB 0/IpCR
VariableLevelsNumber of patients (%)% RCB 0/IOR (95% CI)P% pCROR (95% CI)P
HRNondeficient20 (29%)30Reference10
deficiency statusDeficient50 (71%)685.86 (1.33–25.7)0.012424.06 (0.67–24.6)0.098
TumorII17 (24%)53Reference12
gradeIII53 (76%)580.69 (0.18–2.69)0.59404.58 (0.83–25.3)0.055
ClinicalI9 (13%)89Reference44
stageII51 (73%)570.05 (0.00–0.58)330.26 (0.04–1.56)
III10 (14%)300.02 (0.00–0.35)0.0042200.20 (0.02–2.20)0.29
Chemotherapy4 cycles11 (16%)55Reference18
cycles6 cycles59 (84%)580.93 (0.19–4.60)0.93363.48 (0.58–21.1)0.15
Age at diagnosis (yrs)OR per IQR = 14 0.51 (0.23–1.13)0.087OR per IQR = 14 0.47 (0.19–1.15)0.085
B. Cisplatin Trials Cohort (N = 50)
RCB 0/IpCR
VariableLevelsNumber of patients (%)% RCB 0/IOR (95% CI)P% pCRORa (95% CI)P
HRNondeficient21 (42%)10Reference0
deficiency statusDeficient29 (58%)5212.1 (1.97–74.0)0.0017288.42 (0.93–1697)0.014
TreatmentCisplatin18 (36%)28Reference17
Cisplatin + bevacizumab32 (64%)382.27 (0.51–10.0)0.27161.20 (0.22–8.53)0.62
Tumor size (cm)34OR per IQR = 1.3 1.48 (0.39–5.56)0.5616OR per IQR = 1.3 2.97 (0.64–0.90)0.11
BaselineNegative27 (54%)26Reference11Reference
nodal statusPositive23 (46%)431.85 (0.08–38.4)0.71225.62 (0.16–273)0.26
ClinicalIIA25 (50%)24Reference8Reference
stageIIB21 (42%)431.29 (0.04–44.7)290.49 (0.01–24.3)
IIIA4 (8%)501.30 (0.00–1076)0.9900.03 (0.00–53.9)0.28
Age at diagnosis (yrs)34OR per IQR = 14 0.68 (0.22–2.15)0.5116OR per IQR = 14 0.47 (0.08–2.30)0.47
  • aConfidence intervals fit by profile likelihood.